Publisher Summary
This chapter discusses the epidemiology, clinical features, diagnosis, and management of the multiple system atrophy (MSA). MSA is a progressive sporadic degenerative disease of the central and autonomic nervous systems of an unknown cause. Clinically, it manifests as a motor disorder, incorporating parkinsonism, cerebellar, or pyramidal features, together with urogenital or cardiovascular autonomic involvement. The population prevalence of MSA has been estimated at 4/100,000, although with wide confidence intervals. The commonest cause for misdiagnoses of MSA is Parkinson's disease (PD). Cases of progressive supranuclear palsy (PSP), corticobasal degeneration, and cerebrovascular disease, particularly when it coexists with PD, can sometimes be difficult to differentiate. It is important to make a definitive diagnosis. Unfortunately, especially early in the disease course, this may not yet be possible and the diagnosis may need to be reviewed at intervals. For many patients, paramedical intervention—physiotherapy, occupational therapy, speech therapy, social work, and an expert wheelchair clinic assessment—may give most benefits.
[1]
Peter L. Lantos,et al.
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)
,
1989,
Journal of the Neurological Sciences.
[2]
N P Quinn,et al.
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.
,
1994,
Brain : a journal of neurology.
[3]
G M SHY,et al.
A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study.
,
1960,
Archives of neurology.
[4]
N. Quinn,et al.
Multiple system atrophy--the nature of the beast.
,
1989,
Journal of neurology, neurosurgery, and psychiatry.
[5]
D. Oppenheimer,et al.
Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy.
,
1969,
Journal of neurology, neurosurgery, and psychiatry.